Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
PubMed laboratory research record [PMID: 2980346] PubMed record related to this compound for laboratory literature review
one Phase II skin trial Evidence gap / no head-to-head or combination RCT exists as of 2025 Typical sermorelin dose / 200-500 mcg subcutaneous injection at bedtime Typical GHK-Cu dose / 1-2 mg subcutaneous or topical, 5 days per week Regulatory status / sermorelin: FDA-approved (NDA 19-559, withdrawn 2008 for commercial reasons)
Lifestyle Choices Hydration, balanced diet, and avoiding smoking or excessive alcohol help preserve skin health
These changes included mucosal erosion, ulcerative lesions, deformation and distortion of colonic recesses, extensive infiltration of inflammatory cells (primarily lymphocytes and neutrophils) in the mucosa and submucosa, and depletion of goblet cells
